Nathan Hardy's most recent trade in Sana Biotechnology Inc was a trade of 301,875 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 7, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sana Biotechnology Inc | Nathan Hardy | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 301,875 | 301,875 | - | - | Stock Option (Right to Buy) | |
| Sana Biotechnology Inc | Nathan Hardy | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 67,083 | 67,083 | - | - | Restricted Stock Units | |
| Sana Biotechnology Inc | Nathan Hardy | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 200,000 | 200,000 | - | - | Stock Options (Right to Buy) | |
| Sana Biotechnology Inc | Nathan Hardy | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 225,000 | 225,000 | - | - | Stock Options (Right to Buy) |